Tenofovir News and Research

RSS

U.S. PTO's rejection of Gilead's antiretroviral patents might affect applications in India

Last week's rejection by the U.S. Patent and Trademark Office of four patents on Gilead Sciences' antiretroviral drug Viread might affect patent applications for the drug in India, the Times of India reports.

28 Jan 2008

Anti-retrovirals given daily before and after exposure to HIV prevent vaginal transmission AIDS virus

Prescription drugs now used to treat human immunodeficiency virus infection in adults may prevent the vaginal transmission of HIV, researchers at UT Southwestern Medical Center have found.

15 Jan 2008

HIV drug resistance risk in mothers reduced by tenofovir/emtricitabine with nevirapine during labor

New research from the University of Alabama at Birmingham (UAB) shows that adding a single dose of two common anti-HIV drugs can prevent HIV-positive pregnant women from developing resistance to an entire class of drugs, potentially improving future treatment options.

14 Nov 2007

U.S. trial of new microbicide for HIV prevention to be tested in young women

Nearly half of all people infected with HIV/AIDS are now women, the majority of whom contracted the disease through sexual intercourse with male partners.

10 Jul 2007

Pre-exposure prophylaxis for HIV infection

Clinical trials of pre-exposure prophylaxis - that is giving anti-retroviral drugs to non-HIV-infected individuals to prevent them becoming infected - are exploring whether the approach could lead to a large decrease in transmission of the virus with few or no side effects.

8 Jul 2007

Clinton to the rescue again!

Bill Clinton has done deal with two generic drug companies which will ensure that developing countries will be able to access second line anti-retroviral AIDS drugs at reduced prices.

8 May 2007

Bristol-Myers Squibb receives FDA approval for new formulation of antiretroviral Reyataz

Bristol-Myers Squibb on Friday announced that it has received FDA approval for a single 300 mg capsule formulation of its protease inhibitor Reyataz to be taken as part of combination therapy, Reuters reports.

24 Oct 2006

China taking steps to control the spread of HIV

Zunyu Wu, director of the National Center for AIDS/STD Control and Prevention at China's Center for Disease Control and Prevention on Tuesday at the XVI International AIDS Conference in Toronto said the country plans to continue taking steps to control the spread of HIV in the country, AFP/Today Online reports.

17 Aug 2006

FDA approves Atripla for the treatment of HIV-1 infection in adults

Bristol-Myers Squibb Company and Gilead Sciences have announced the U.S. Food and Drug Administration (FDA) has granted approval of Atripla (efavirenz 600 mg/ emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg) for the treatment of HIV-1 infection in adults.

13 Jul 2006

FDA approves Atripla three-drug combination tablet for treatment of HIV-1

FDA approves Atripla Tablets, a fixed-dose combination of three widely-used antiretroviral drugs.

12 Jul 2006

SLU Liver Center to study effectiveness of tenofovir in treating hepatitis B

Saint Louis University School of Medicine researchers are studying the effectiveness of a drug for patients with chronic hepatitis B that is currently used to treat HIV.

3 May 2006

Outcome of patients with hepatitis B and HIV infections referred for liver transplantation

A new study on HIV patients who also had Hepatitis B virus (HBV) found that better outcomes are possible if they are referred early for transplant and treated with a combination of drugs for HBV. It is essential to monitor the HBV status of these patients, however, in order to control the emergence of drug-resistant HBV infection.

3 May 2006

Clinical trials of daily oral antiretroviral dosing as pre-exposure prophylaxis

Writing in the journal Science, an international team of researchers, clinicians and others explains that a promising, relatively new approach is for people not infected but at high risk to take drugs that might prevent them from contracting HIV. But debate over the particulars of the strategy has slowed progress.

3 Oct 2005

Media reports of drug trials can lack accuracy and reliability

Media reports of drug trials can lack accuracy and reliability, according to a study published in the open access journal BMC International Health and Human Rights.

25 Aug 2005

Activist groups hinder important clinical trials of HIV medication

One promising approach to help stem the global HIV epidemic is to give commercial sex workers an HIV medication (such as the drug tenofovir) before they have high risk sex in the hope of reducing their chances of becoming infected, an approach called "pre-exposure prophylaxis" (PREP).

19 Jul 2005

Approval of fixed-dose combination treatments for HIV-1 infection

The Food and Drug Administration has announced the approvals of Epzicom (abacavir/lamivudine) and Truvada (tenofovir disoproxil/emtricitabine), two fixed-dose combination treatments for HIV-1 infection.

5 Aug 2004

FDA approves two fixed-dose combination treatments for HIV-1 infection

The Food and Drug Administration has announced approved Epzicom (abacavir/lamivudine) and Truvada (tenofovir disoproxil/emtricitabine), two fixed-dose combination treatments for HIV-1 infection.

2 Aug 2004

Comparison of antiretroviral therapies shows that tenofovir DF and stavudine are equally effective

Results from a three year double-blinded trial which compared antiretroviral therapies show that the combination regimens of tenofovir DF and stavudine, are equally effective, though tenofovir DF has more favorable outcomes with respect to cholesterol levels and the nervous system.

11 Jul 2004

Relatively difficult for the AIDS virus to develop resistance to the drug, tenofovir, or the DAPY (diarylpyrimidine) family of compounds

HIV is a moving target, unpredictably changing direction to elude anti-AIDS drugs, but researchers at Rutgers are clearly on the track of solutions to combat HIV drug resistance.

29 Jun 2004

Plans for once-daily, fixed-dose combination of three anti-HIV drugs

Bristol-Myers Squibb Company, Gilead Sciences, Inc. and Merck & Co., Inc. have announced that they are in discussions on the development of a once-daily, fixed-dose combination of three anti-HIV drugs and are also considering certain co-packaging options for the individual products.

16 May 2004